Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate tablets.

Rizatriptan Benzoate tablets are the generic equivalent of Merck and Co’s Maxalt tablets and are indicated for the acute treatment of migraine with or without aura in adults and in paediatric patients of 6-17 years old.

The annual sale of the product is approximately $300 million for the 12 months ended March 2012, according to IMS.

The product was ready for launch, the Hyderabad-based company said in a release.

(This article was published on January 1, 2013)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.